Direct Relief and The Pfizer Foundation announced today new grantees for their infectious disease program, awarding $4.5 ...

The FDA approves blood test to guide breast cancer therapy by detecting ESR1 mutations for targeted treatment selection.

Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its ...

Novavax (NASDAQ:NVAX) executives used the company’s first-quarter 2026 earnings call to highlight continued progress in ...

Novavax ended the first quarter of 2026, with $818 million in cash and accounts receivables. We added $80 million of nondilutive cash in the first quarter of 2026, including a $30 million Pfizer ...

Several major biopharma and diagnostics companies reported strong Q1 2026 results and outlined ambitious precision medicine strategies, including expanded genetic testing, targeted cancer therapies, ...

First Tracks Biotherapeutics, spun off from AnaptysBio, launches with $180M cash and a diverse, early-stage pipeline. Read ...

The drugmaker said both late-stage Vanquish studies are fully enrolled ahead of schedule. ・EO Brian Lian said Viking expects to have four late-stage trials underway by the end of 2026. ・Competition in ...

A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech ...

A Bristol Myers Squibb plant that makes cancer drugs was the only manufacturer in the U.S. recognized for innovation by the ...

Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2026 ...

China's Sunshine Lake Pharma has won US Food and Drug Administration approval for its insulin glargine injection, marking the ...